Conway Sarah, Saxena Shrishti, Baecher-Allan Clare, Krishnan Rajesh, Houtchens Maria, Glanz Bonnie, Saraceno Taylor J, Polgar-Turcsanyi Mariann, Bose Gauruv, Bakshi Rohit, Bhattacharyya Shamik, Galetta Kristin, Kaplan Tamara, Severson Christopher, Singhal Tarun, Stazzone Lynn, Zurawski Jonathan, Paul Anu, Weiner Howard L, Healy Brian C, Chitnis Tanuja
Department of Neurology, Brigham Multiple Sclerosis Center, Brigham and Women's Hospital, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Mult Scler J Exp Transl Clin. 2023 Apr 5;9(2):20552173231165196. doi: 10.1177/20552173231165196. eCollection 2023 Apr-Jun.
There is limited knowledge about T cell responses in patients with multiple sclerosis (MS) after 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine.
Assess the SARS-CoV-2 spike antibody and T cell responses in MS patients and healthy controls (HCs) after 2 doses (2-vax) and 3 doses (3-vax) of SARS-CoV-2 mRNA vaccination.
We studied seroconversion rates and T cell responses by flow cytometry in HC and MS patients on fingolimod or ocrelizumab.
After 2-vax, 8/33 (24.2%) patients in ocrelizumab group, 5/7 (71.4%) in fingolimod group, and 29/29 (100%) in HC group ( = 5.7 × 10) seroconverted. After 3-vax, 9/22 (40.9%) patients in ocrelizumab group, 19/21 (90.5%) in fingolimod group, and 7/7 (100%) in HC group seroconverted (= 0.0003). The percentage of SARS-CoV-2 peptide reactive total CD4+ T cells increased in HC and ocrelizumab group but not in fingolimod group after 2-vax and 3-vax (< 0.0001). The percentage of IFNγ and TNFα producing total CD4+ and CD8+ T cells increased in fingolimod group as compared to HC and ocrelizumab group after 2-vax and 3-vax (< 0.0001).
MS patients on ocrelizumab and fingolimod had attenuated humoral responses, but preserved cytokine producing T cell responses compared to HCs after SARS-CoV-2 mRNA vaccination.
NCT05060354.
对于接受3剂严重急性呼吸综合征冠状病毒2（SARS-CoV-2）mRNA疫苗后的多发性硬化症（MS）患者的T细胞反应，人们了解有限。
评估MS患者和健康对照（HC）在接种2剂（2针）和3剂（3针）SARS-CoV-2 mRNA疫苗后的SARS-CoV-2刺突抗体和T细胞反应。
我们通过流式细胞术研究了接受芬戈莫德或奥瑞珠单抗治疗的HC和MS患者的血清转化率和T细胞反应。
接种2针后，奥瑞珠单抗组8/33（24.2%）患者、芬戈莫德组5/7（71.4%）患者和HC组29/29（100%）患者（=5.7×10）发生血清转化。接种3针后，奥瑞珠单抗组9/22（40.9%）患者、芬戈莫德组19/21（90.5%）患者和HC组7/7（100%）患者发生血清转化（=0.0003）。接种2针和3针后，HC组和奥瑞珠单抗组中对SARS-CoV-2肽反应性的总CD4+T细胞百分比增加，但芬戈莫德组未增加（<0.0001）。与HC组和奥瑞珠单抗组相比，接种2针和3针后，芬戈莫德组中产生IFNγ和TNFα的总CD4+和CD8+T细胞百分比增加（<0.0001）。
与HC相比，接受奥瑞珠单抗和芬戈莫德治疗的MS患者在接种SARS-CoV-2 mRNA疫苗后体液反应减弱，但产生细胞因子的T细胞反应得以保留。
NCT05060354。
